[HTML][HTML] DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

RX Huang, PK Zhou - Signal transduction and targeted therapy, 2020 - nature.com
Radiotherapy is one of the most common countermeasures for treating a wide range of
tumors. However, the radioresistance of cancer cells is still a major limitation for …

[HTML][HTML] Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight”

R Eychenne, M Chérel, F Haddad, F Guérard… - Pharmaceutics, 2021 - mdpi.com
Among all existing radionuclides, only a few are of interest for therapeutic applications and
more specifically for targeted alpha therapy (TAT). From this selection, actinium-225 …

[HTML][HTML] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre …

A Gafita, J Calais, TR Grogan, B Hadaschik… - The Lancet …, 2021 - thelancet.com
Summary Background Lutetium-177 (177 Lu) prostate-specific membrane antigen (177 Lu-
PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate …

ICRU REPORT 96, dosimetry-guided radiopharmaceutical therapy

G Sgouros, WE Bolch, A Chiti… - Journal of the …, 2021 - journals.sagepub.com
The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

225Ac-PSMA-617 for therapy of prostate cancer

C Kratochwil, U Haberkorn, FL Giesel - Seminars in nuclear medicine, 2020 - Elsevier
Prostate-specific membrane antigen (PSMA)-targeting radio-ligand therapy with beta-
emitting 177 Lutetium has already been investigated in several early phase dosimetry …

Prognostic role of DNA damage response genes mutations and their association with the sensitivity of olaparib in prostate cancer patients

D Zhang, X Xu, Y Wei, X Chen, G Li, Z Lu… - Cancer …, 2022 - journals.sagepub.com
Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …

The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer

P Deegen, O Thomas, O Nolan-Stevaux, S Li… - Clinical Cancer …, 2021 - AACR
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) remains a disease with
high unmet medical need, as most patients do not achieve durable response with available …

Using PSMA imaging for prognostication in localized and advanced prostate cancer

MJ Roberts, T Maurer, M Perera, M Eiber… - Nature Reviews …, 2023 - nature.com
The use of prostate-specific membrane antigen (PSMA)-directed applications in modern
prostate cancer management has evolved rapidly over the past few years, helping to …

[HTML][HTML] Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer

A Juzeniene, VY Stenberg, ØS Bruland, RH Larsen - Cancers, 2021 - mdpi.com
Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis

S Satapathy, A Sood, CK Das, BR Mittal - Prostate Cancer and Prostatic …, 2021 - nature.com
Background Targeted radionuclide therapy with Actinium-225-labeled prostate-specific
membrane antigen ligands (225Ac-PSMA) has emerged as a promising treatment modality …